4//SEC Filing
Paull Robert Bradley 4
Accession 0001104659-20-078317
CIK 0001479419other
Filed
Jun 28, 8:00 PM ET
Accepted
Jun 29, 9:51 PM ET
Size
8.8 KB
Accession
0001104659-20-078317
Insider Transaction Report
Form 4
Paull Robert Bradley
Director10% Owner
Transactions
- Other
Common Stock
2018-05-18+597→ 597 total(indirect: See Footnote) - Other
Common Stock
2018-06-11+477→ 1,074 total(indirect: See Footnote) - Other
Common Stock
2020-03-11+1,287→ 2,361 total(indirect: See Footnote)
Footnotes (3)
- [F1]Pro rata distribution for no consideration to the reporting person from Lux Ventures II, L.P., of which the reporting person is a non-managing member.
- [F2]Prior reports filed on July 19, 2017 and July 26, 2017 by the reporting person overstated the number of shares beneficially owned by Mr. Paull by 1,204,937 shares by incorrectly reporting that Mr. Paull had beneficial ownership of 1,156,441 shares held directly by Lux Ventures II, L.P. and 48,496 shares held by Lux Ventures II Sidecar, L.P.
- [F3]These shares are owned directly by The paull Revocable Trust U/A/D 04/06/2012 (the "Trust"), and indirectly by Mr. Paull as co-trustee of the Trust.
Documents
Issuer
Kala Pharmaceuticals, Inc.
CIK 0001479419
Entity typeother
Related Parties
1- filerCIK 0001711254
Filing Metadata
- Form type
- 4
- Filed
- Jun 28, 8:00 PM ET
- Accepted
- Jun 29, 9:51 PM ET
- Size
- 8.8 KB